Organizations. Job functions. Regions.
Excitement is growing around the potential of human microbiome therapeutics, with the amount of research, number of companies and products ever increasing within the emerging field. However, at what stage is the industry truly at in the key areas of research and development, manufacturing and formulation, commercialization and business development, and regulations?
In December 2018 KNect365 Life Sciences conducted one of the largest surveys of its kind across microbiome therapeutics professionals around the world. This final report based on 144 responses reveals unique insights into the state of the industry today going into 2019; the hottest potential opportunities, the biggest challenges and how industry insiders are tackling them.
With an even split between European and North American-based respondents, the results offer a global view of microbiome therapeutics and some interesting comparisons between the two regions. Additionally, with half describing their job function as VP, Head, Director or Project Leader, it offers a senior view of the industry.
As expected, respondents worked for pharma and biotech companies (47%) more than any other organization, followed by service providers, consultants and medical device companies (17%) and academic institutions (16%).
The range of responses from those who don't work in one of the available survey options shows how broad the human microbiome therapeutics field currently is - including:
Interestingly, the companies working within the field tend to be either very small or large. 25% of respondents work for a company of less than 10 people and 37% for one of over 250 employees. This is probably a result of the fact that the field is relatively new, meaning that there are a number of new start-ups, whilst larger companies are able to devote resources to the research.
